Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 5/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29477149 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1EGFRSRCGAA | |
| SCHEMBL4975424 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1EGFRSRCGAA | |
| SCHEMBL2961716 | 0.80 | CNR1 (0.54) | KDM4EALDH1A1 | |
| SCHEMBL3382621 | 0.80 | ALDH1A1 (0.73) | KDM4EALDH1A1EGFRSRCGAA | |
| SCHEMBL29942151 | 0.80 | CNR1 (0.54) | KDM4EALDH1A1 | |
| SCHEMBL30254999 | 0.80 | ALDH1A1 (0.73) | KDM4EALDH1A1EGFRSRCGAA | |
| SCHEMBL3069354 | 0.79 | KDM4E (0.68) | KDM4EALDH1A1FOLH1LMNA | |
| SCHEMBL3383887 | 0.78 | CHRNB2 (0.54) | KDM4EALDH1A1EGFRSRCGAA | |
| SCHEMBL10965773 | 0.76 | KDM4E (0.52) | KDM4EALDH1A1EGFRSRCGAA | |
| SCHEMBL5281305 | 0.75 | KDM4E (0.54) | KDM4EALDH1A1EGFRSRCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262215-B2 | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors | NAD AG (DE) | 2007-08-28 | — | — | US | disclosed |
| US-7262215-B2 | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors | NAD AG (DE) | 2007-08-28 | — | — | US | disclosed |
| CN-1068588-C | 1H-indole-3-acetamide splA2 inhibitors | LILLY CO ELI (US) | 2001-07-18 | — | — | CN | disclosed |
| US-6252084-B1 | THERAPY FOR SEPSIS SHOCK | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0620215-B1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | LILLY CO ELI (US) | 1999-08-18 | — | — | EP | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| CN-1098715-A | PLA 2 inhibitors 1H-indole-3-acetamide compounds | LILLY CO ELI (US) | 1995-02-15 | — | — | CN | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |